Publications
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Treatment of patients with recurrent/refractory aggressive non-Hodgkin's lymphoma: effectiveness and safety of pixantrone2016 | Faculty of Medicine in Hradec Králové
- Therapy of severe haemorrhagic disorders and severe haemorrhagy +12008 | Faculty of Medicine in Hradec Králové
- News in therapy and prevention of venous thromboembolism +12008 | Faculty of Medicine in Hradec Králové
- Haemocoagulation and renal insufficiency, haemocoagulation and type 2 diabetes mellitus +12008 | Faculty of Medicine in Hradec Králové
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group2023 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen
- Pulmonary damage in a patient with hairy cell leukemia - infectious involvement or hematological disease activity? Case report2023 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia - cardiovascular complications and bleeding2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
Loading network view...
